摘要
背景:该研究有两个目的(1)为了评估在正常认知人群神经心理功能的变化,其也许先于临床症状的发作。(2)为了检测载脂蛋白E (ApoE )基因对这些变化的影响。方法:268名认知正常的人预期完成了纵向神经心理、临床评估和达成一致的诊断。平均随访时间为9.2年(+/- 3.3)。208名参与者依然正常,60参与者已发展为认知障碍,与MCI或者痴呆的诊断一致。完成了对基准率分数和分数的变化率Cox 回归分析,涉及临床症状发作时间的关系。对ApoE-4携带者或非携带者状态进行了分析。检测了与ApoE-4 状态的反应。结果:较低的基准测试分数和变化率测试分数与临床症状发作时间有一定关联(P<0.001)。基线到临床症状发作的平均时间是6.15 (+/- 3.4)。ApoE-4基因存在加倍进展的风险。在这两项测试中,ApoE-4携带者和非携带者分数的变化率有显著区别。 结论:认知衰退遭遇临床症状的发作,可以作为MCI前兆诊断。正常人持续的认知衰退变化也许至少6.5年才可以观察到,但是先于症状发作。此外,ApoE-4基因携带者有双倍的衰退风险。
关键词: 载脂蛋白E基因,认知衰退,情景记忆,纵向随访,轻度认知功能障碍,临床前阿尔茨海默病
Current Alzheimer Research
Title:Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype
Volume: 11 Issue: 8
Author(s): Marilyn Albert, Anja Soldan, Rebecca Gottesman, Guy McKhann, Ned Sacktor, Leonie Farrington, Maura Grega, Raymond Turner, Yi Lu, Shanshan Li, Mei-Cheng Wang and Ola Selnes
Affiliation:
关键词: 载脂蛋白E基因,认知衰退,情景记忆,纵向随访,轻度认知功能障碍,临床前阿尔茨海默病
摘要: Background: This study had two goals (1) to evaluate changes in neuropsychological performance among cognitively normal individuals that might precede the onset of clinical symptoms, and (2) to examine the impact of Apolipoprotein E (ApoE) genotype on these changes. Methods: Longitudinal neuropsychological, clinical assessments and consensus diagnoses were completed prospectively in 268 cognitively normal individuals. The mean duration of follow-up was 9.2 years (+/- 3.3). 208 participants remained normal and 60 developed cognitive decline, consistent with a diagnosis of MCI or dementia. Cox regression analyses were completed, for both baseline scores and rate of change in scores, in relation to time to onset of clinical symptoms. Analyses were completed both with and without ApoE-4 status included. Interactions with ApoE-4 status were also examined. Results: Lower baseline test scores, as well as greater rate of change in test scores, were associated with time to onset of clinical symptoms (p<0.001). The mean time from baseline to onset of clinical symptoms was 6.15 (+/- 3.4) years. The presence of an ApoE-4 allele doubled the risk of progression. The rate of change in two of the test scores was significantly different in ApoE-4 carriers vs. non-carriers. Conclusions: Cognitive performance declines prior to the onset of clinical symptoms that are a harbinger of a diagnosis of MCI. Cognitive changes in normal individuals who will subsequently decline may be observed at least 6.5 years prior to symptom onset. In addition, the risk of decline is doubled among individuals with an ApoE-4 allele.
Export Options
About this article
Cite this article as:
Marilyn Albert, Anja Soldan, Rebecca Gottesman, Guy McKhann, Ned Sacktor, Leonie Farrington, Maura Grega, Raymond Turner, Yi Lu , Shanshan Li, Mei-Cheng Wang and Selnes Ola, Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype, Current Alzheimer Research 2014; 11 (8) . https://dx.doi.org/10.2174/156720501108140910121920
DOI https://dx.doi.org/10.2174/156720501108140910121920 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients
Current Alzheimer Research Prevalence of Pathogenic Mutations in an Italian Clinical Series of Patients with Familial Dementia
Current Alzheimer Research Trophic Effect of Glutamate
Current Topics in Medicinal Chemistry Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Protein Chemistry of Amyloid Fibrils and Chaperones: Implications for Amyloid Formation and Disease
Current Chemical Biology Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Hippocampal Morphology and Autobiographic Memory in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets The Emerging Role of MicroRNA in Schizophrenia
CNS & Neurological Disorders - Drug Targets Editorial: The microRNA 221/222 Cluster: Inaugurating a New Era in Cardiovascular Disease and Cancer?
Current Vascular Pharmacology Prevention of Cardiovascular Diseases with Anti-Inflammatory and Anti- Oxidant Nutraceuticals and Herbal Products: An Overview of Pre-Clinical and Clinical Studies
Recent Patents on Inflammation & Allergy Drug Discovery A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Conference Report: 6<sup>th</sup> Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Nov 14-16, 2013, The Westin San Diego Gaslamp Quarter Hotel, San Diego, CA, USA
CNS & Neurological Disorders - Drug Targets Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease
Current Alzheimer Research Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets A Nanotechnological Approach to the Management of Alzheimer Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets An Insight into the Therapeutic Potential of Major Coffee Components
Current Drug Metabolism Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices
Current Alzheimer Research